PDF(Pubmed)
Abstract：
(1) Background: The current study aimed to compare two of the most frequently prescribed preservative-free (PF) antiglaucoma drops, (Latanoprost PF vs. Bimatoprost PF) in promoting OSD in patients with POAG. (2) Methods: In this prospective study, 44 eyes from 44 participants were included. In the control group we enrolled 24 eyes, 11 eyes treated only with Latanoprost PF were enrolled in the Latanoprost PF group, and 9 eyes treated only with Bimatoprost PF in the Bimatoprost PF group. In all eyes, we evaluated the ocular levels of MMP-9 using the InflammaDry kit. We also performed Schirmer\'s test and the TBUT test. (3) Results: We found elevated ocular levels of MMP-9 (>40 ng/mL) in the Bimatoprost PF group (88.89% of the participants) compared to the control (8.33%) and the Latanoprost PF group (27.27%), and the difference was statistically significant (p < 0.001). The Schirmer\'s test values were statistically significantly lower in the Bimatoprost PF group compared to the other two groups. Additionally, the TBUT values were lower in the Bimatoprost PF group compared to the control group, and the difference was statistically significant. (4) Conclusions: Latanoprost PF eye drops treat the ocular surface better and they do not induce overexpression of MMP-9, a molecule that is related to OSD.
摘要：
（1）背景：本研究旨在比较两种最常用的无防腐剂（PF）抗青光眼滴剂，（拉坦前列素PF与比马前列素PF）促进POAG患者的OSD。(2)方法：在本前瞻性研究中，包括44名参与者的44只眼睛。在对照组中，我们招募了24只眼，仅接受拉坦前列素PF治疗的11只眼纳入拉坦前列素PF组，比马前列素PF组仅用比马前列素PF治疗9只眼。在所有的眼睛，我们使用inflammaDry试剂盒评估了眼部MMP-9的水平。我们还进行了Schirmer测试和TBUT测试。（3）结果：我们发现比马前列素PF组（88.89％的参与者）与对照组（8.33％）和拉坦前列素PF组（27.27％）相比，眼部MMP-9水平升高（>40ng/mL），差异有统计学意义(p<0.001)。比马前列素PF组的Schirmer检验值在统计学上显著低于其他两组。此外,与对照组相比，比马前列素PF组的TBUT值较低，差异有统计学意义。（4）结论：拉坦前列素PF滴眼液对眼表的治疗效果较好，并且不会引起与OSD相关的MMP-9的过度表达。
